# chronic obstructive pulmonary disease (COPD) - glm-5.2

- Benchmark system: E2seq + Agent RAG
- Repeat: 2
- Task type: DISEASE-STATE
- Tissue / sample source: lung tissue
- Comparison or endpoint: COPD versus normal control
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Zhipu AI / glm-5.2
- Message SHA-256: 75cb1462dc859d10e673df1637d9bfb35fbfd41f53bda923e17881eee80cc2ef
- Response HTTP status: 200
- Prompt tokens: 17302
- Completion tokens: 6355
- Reasoning tokens: 0
- Total tokens: 23657
- API requests reported: 1
- Elapsed seconds: 136.037
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 936.215
- Question handoff seconds: 951.58
- Final benchmark system: E2seq; file rank 1/5; original repeat 2; model vendor: Zhipu AI

---
# Multidimensional Interpretation of COPD Lung Tissue Transcriptomic Results

## Data Quality Warning

The uploaded differential expression results for COPD versus normal lung tissue contain 100 unique selected genes (83 upregulated, 17 downregulated), with 77 passing FDR ≤ 0.01. Four duplicate rows were identified and resolved by the ledger (MACF1, CLDN16, AAK1, NCR3LG1). **A critical compositional concern is that the gene list is dominated by antisense lncRNAs, uncharacterized LOC loci, pseudogene-derived transcripts, and small non-coding RNAs** (e.g., RN7SK, RNA18SN5, SNORD60, SCARNA9, SNORA70), which together comprise the majority of selected features. This raises the possibility that the differential signal partially reflects non-coding RNA regulatory shifts, altered rRNA/snRNA biogenesis, or platform-level artifacts rather than purely protein-coding disease biology. The following interpretation proceeds with this caveat and separates protein-coding gene programs from non-coding RNA programs accordingly.

**External statistical validation was not performed.** No independent cohort statistic is available; all external database and literature records serve only as contextual annotation, not replication.

---

## 1. Overall Biological Interpretation

The COPD lung tissue signature is characterized by three interlocking themes:

1. **Pervasive antisense and non-coding RNA dysregulation.** The single largest pattern is upregulation of antisense transcripts paired to protein-coding genes involved in signaling, cytoskeletal regulation, metabolism, and immune function (e.g., *TGFB2-AS1*, *LRP1-AS*, *SERPINB9-AS1*, *INHBA-AS1*, *KAT6A-AS1*, *PRKCH-AS2*, *ZMYM4-AS1*). This suggests a broad alteration of post-transcriptional or epigenetic regulatory layers in COPD lung tissue, consistent with the known role of lncRNAs in inflammatory and fibrotic lung disease.

2. **Pro-fibrotic and TGF-β–associated signaling.** Upregulation of *GREM1* (log2FC = 1.65, FDR = 0.0072), *TGFB2-AS1* (log2FC = 1.04, FDR = 0.0074), *INHBA-AS1* (log2FC = 1.19, FDR = 0.0136), and *FGG* (log2FC = 1.76, FDR = 0.0053) collectively points toward activation of extracellular matrix remodeling and BMP/TGF-β/activin signaling, pathways central to the small-airway fibrosis and parenchymal destruction characteristic of COPD.

3. **Immune and antimicrobial response shifts.** Upregulation of *DEFB1* (log2FC = 1.40, FDR = 0.0074), *IGKV1-8* (log2FC = 1.84, FDR = 0.0009), *NCR3LG1* (log2FC = 0.95, FDR = 0.0045), and *PTPRCAP* (downregulated, log2FC = −0.87, FDR = 0.0168) suggests altered innate and adaptive immune activity, potentially reflecting chronic infection, B-cell infiltration, or NK-cell ligand modulation in the COPD lung microenvironment.

Downregulated features are fewer and include *UQCRBP1* (log2FC = −1.20, FDR = 3.13e-06), *RPL23AP32* (log2FC = −1.66, FDR = 0.000136), and *RASSF7* (log2FC = −0.91, FDR = 0.0024), suggesting possible reductions in mitochondrial translation-associated processes and Ras-signaling family components, though these interpretations are limited by the pseudogene/fragment nature of several of these transcripts.

---

## 2. Core Biological Programs

### Program 1: Antisense lncRNA–Mediated Regulatory Reprogramming

**Direction:** Upregulated (overwhelmingly)

**Major supporting genes:** *TGFB2-AS1*, *LRP1-AS*, *SERPINB9-AS1*, *INHBA-AS1*, *KAT6A-AS1*, *PRKCH-AS2*, *ZMYM4-AS1*, *SYNE1-AS1*, *USP6NL-AS1*, *LDLR-AS1*, *BCAT1-AS1*, *EEF1DP3*, *ANP32A-IT1*, *KLF9-DT*, *TIPARP-AS1*, *UBXN7-AS1*, *HDLBP-AS1*, *POMGNT2-AS1*, *NPHP3-AS1*, *MDN1-AS1*

**Standardized pathway/ontology:** No single standardized GO/Reactome term covers antisense transcription as a unified process. The Reactome module R-HSA-9827615 (GATA6-AS1 lncRNA) was retrieved for *CELF2-AS1*, *LRRC37A2-AS1*, *SERPINB9-AS1*, and *TIPARP-AS1*, providing a limited pathway-level anchor.

**Explanation:** The sheer number of upregulated antisense transcripts—many paired to genes with established roles in TGF-β signaling (*TGFB2-AS1*), lipid metabolism (*LDLR-AS1*), serpin biology (*SERPINB9-AS1*), and kinase signaling (*PRKCH-AS2*)—suggests a coordinated shift in cis-regulatory or post-transcriptional control. In COPD, chronic inflammation and oxidative stress are known to alter lncRNA landscapes; the breadth of this signal implies it is a program-level phenomenon rather than an isolated event.

**Strength:** Strong direct statistical support (multiple antisense transcripts with FDR < 0.01). **Limitation:** Most antisense transcripts lack functional characterization; pathway annotation is sparse; the biological consequence of each antisense transcript on its sense partner cannot be determined from expression data alone.

---

### Program 2: TGF-β / BMP Signaling and Extracellular Matrix Remodeling

**Direction:** Upregulated

**Major supporting genes:** *GREM1*, *TGFB2-AS1*, *INHBA-AS1*, *FGG*, *MACF1*

**Standardized pathway:** Hallmark TGF-β signaling; Reactome extracellular matrix organization (R-HSA-1474244); KEGG TGF-β signaling pathway (hsa04350)

**Explanation:** *GREM1* encodes a BMP antagonist that promotes fibroblast activation and is implicated in idiopathic pulmonary fibrosis. *TGFB2-AS1* is an antisense transcript to *TGFB2*, a key TGF-β ligand. *INHBA-AS1* is antisense to *INHBA* (inhibin β-A), a subunit of activin, which signals through the same SMAD-dependent pathway. *FGG* (fibrinogen gamma chain) is an acute-phase and ECM-associated protein. *MACF1* (log2FC = 1.56, FDR = 4.02e-07) regulates cytoskeletal–ECM cross-talk and Wnt signaling. Collectively, these genes indicate pro-fibrotic signaling activation relevant to the airway wall remodeling and parenchymal destruction in COPD.

**Strength:** Multiple concordant genes across related pathways; *GREM1* and *FGG* are well-characterized protein-coding genes with direct COPD/IPF literature relevance. **Limitation:** Two of the five key contributors (*TGFB2-AS1*, *INHBA-AS1*) are antisense transcripts whose effect on sense-partner expression is unknown; no pathway enrichment P-value was computed from the uploaded data.

---

### Program 3: Innate Immune and Antimicrobial Response

**Direction:** Upregulated

**Major supporting genes:** *DEFB1*, *IGKV1-8*, *NCR3LG1*, *MGAM* (neutrophil degranulation association)

**Standardized pathway:** KEGG *Staphylococcus aureus* infection (hsa05150, via *DEFB1*); Reactome neutrophil degranulation (R-HSA-6798695, via *MGAM*); GO negative regulation of monocyte chemotaxis (GO:0090027) and negative regulation of leukocyte proliferation (GO:0070664)

**Explanation:** *DEFB1* encodes β-defensin-1, an antimicrobial peptide expressed in airway epithelium. *IGKV1-8* represents immunoglobulin kappa light chain variable region, indicating B-cell or plasma-cell infiltration. *NCR3LG1* (NKp30 ligand) modulates NK-cell activation. *MGAM*, while primarily a digestive enzyme, is annotated to the Reactome neutrophil degranulation pathway. The co-occurrence of these genes suggests altered innate and adaptive immune surveillance in COPD lung tissue, potentially secondary to chronic bacterial colonization.

**Strength:** Moderate; supported by direct statistics and GO/KEGG/Reactome annotations. **Limitation:** *IGKV1-8* may reflect clonal B-cell expansion rather than a coordinated immune program; *MGAM* lung expression is very low in GTEx, raising a specificity concern.

---

### Program 4: O-Glycan Biosynthesis and Glycosylation

**Direction:** Upregulated

**Major supporting genes:** *POMK*, *POMGNT2-AS1*, *MGAM*, *CLDN16*

**Standardized pathway:** KEGG mannose-type O-glycan biosynthesis (hsa00513); KEGG galactose metabolism (hsa00052)

**Explanation:** *POMK* (protein O-mannose kinase) phosphorylates O-mannosyl glycans and is essential for α-dystroglycan glycosylation. *POMGNT2-AS1* is antisense to *POMGNT2*, another O-mannosyltransferase in the same pathway. *MGAM* is annotated to galactose metabolism. Altered glycosylation is increasingly recognized in inflammatory airway disease, where mucin glycosylation changes affect mucus rheology and host–pathogen interactions.

**Strength:** Weak-to-moderate; supported by KEGG pathway annotation but by only two directly relevant protein-coding genes. **Limitation:** The biological significance of O-glycan pathway changes in COPD lung tissue is not well-established; this program may reflect altered epithelial cell composition rather than disease-specific glycosylation remodeling.

---

### Program 5: Small Non-Coding RNA and Ribosomal Biogenesis Shift

**Direction:** Mixed (mostly upregulated, some downregulated)

**Major supporting genes:** *RN7SK* (up, log2FC = 1.77, FDR = 3.13e-06), *RNA18SN5/SN1/SN3* (up), *SCARNA9* (up), *SNORD60* (down, log2FC = −0.99, FDR = 0.019), *SNORA70* (down, log2FC = −0.87, FDR = 0.0074), *RPL23AP32* (down, log2FC = −1.66, FDR = 0.000136), *UQCRBP1* (down, log2FC = −1.20, FDR = 3.13e-06), *MIR132* (up, log2FC = 1.65, FDR = 0.000237), *MIR3665* (up), *MIR7846* (up), *MIR2110* (up), *MIR7703* (down)

**Standardized pathway:** No unified standardized pathway; broadly relates to RNA processing, ribosome biogenesis, and miRNA regulatory networks.

**Explanation:** The coordinated upregulation of RN7SK (a non-coding RNA involved in transcriptional pause release and stem-cell maintenance), multiple 18S rRNA fragments, and scaRNAs, alongside downregulation of specific snoRNAs and ribosomal pseudogene fragments, suggests altered RNA processing or ribosomal biogenesis in COPD tissue. *MIR132* upregulation is notable because miR-132 is a well-characterized inflammatory miRNA induced by CREB in response to Toll-like receptor signaling and has been implicated in COPD.

**Strength:** Moderate direct statistical support for multiple non-coding RNA species. **Limitation:** The functional significance of rRNA fragment and snoRNA changes is difficult to interpret; these signals may partly reflect RNA quality, degradation, or computational mapping artifacts rather than genuine disease biology.

---

## 3. Key Genes and Interaction Modules

| # | Gene | Direction (log2FC, FDR) | Role in Core Programs | Gene Relationships |
|---|------|------------------------|----------------------|-------------------|
| 1 | **GREM1** | Up (1.65, 0.0072) | BMP antagonist; pro-fibrotic signaling (Program 2) | Pathway co-membership with TGF-β/BMP signaling; no direct physical interaction evidence among selected genes |
| 2 | **FGG** | Up (1.76, 0.0053) | Fibrinogen gamma; ECM/coagulation (Program 2) | Pathway co-membership with acute-phase and ECM pathways; indirect relationship to TGF-β signaling |
| 3 | **MIR132** | Up (1.65, 0.000237) | Inflammatory miRNA; TLR/CREB-responsive (Program 5) | Regulatory interaction: miR-132 targets multiple mRNAs in inflammatory pathways (literature); no direct interaction evidence within selected genes |
| 4 | **DEFB1** | Up (1.40, 0.0074) | Antimicrobial peptide; innate immunity (Program 3) | Pathway co-membership: KEGG *S. aureus* infection; no direct physical interaction with other selected genes |
| 5 | **POMK** | Up (1.06, 0.00123) | O-mannose kinase; glycosylation (Program 4) | Pathway co-membership: KEGG mannose-type O-glycan biosynthesis; *POMGNT2-AS1* is an antisense transcript to a gene in the same pathway (pathway co-membership, not direct interaction) |
| 6 | **MACF1** | Up (1.56, 4.02e-07) | Cytoskeletal–ECM linker; cytoskeletal remodeling (Program 2) | STRING records exist for MACF1 interactors (e.g., CLASP2, GOLGA4) but none among selected genes; relationship to *FGG* and *GREM1* is pathway-level co-membership only |
| 7 | **AAK1** | Up (0.99, 0.000447) | Adaptor-associated kinase 1; clathrin-mediated endocytosis, signaling | Regulatory interaction: OmniPath/KEA records indicate AAK1 kinase-substrate relationships (source-dependent); no direct physical interaction with other selected genes |
| 8 | **ETV3L** | Up (1.47, 2.75e-11) | ETS-family transcriptional regulator; possible immune/inflammatory regulation | GO annotation: nucleus, DNA-binding transcription factor activity; no regulatory or physical interaction data among selected genes |
| 9 | **IGKV1-8** | Up (1.84, 0.000859) | Immunoglobulin kappa light chain; B-cell/plasma cell marker (Program 3) | Pathway co-membership: immune receptor signaling; no direct interaction with other selected genes |
| 10 | **TGFB2-AS1 / INHBA-AS1 module** | Both up (1.04/0.0074; 1.19/0.0136) | Antisense transcripts to TGF-β family ligands; pro-fibrotic regulatory layer (Programs 1 & 2) | Putative cis-regulatory interaction with sense partners *TGFB2* and *INHBA* (not directly measured); no direct physical interaction evidence |

**Relationship type clarifications:**
- **Direct physical interaction:** No direct physical interactions were identified among the selected genes in this dataset. STRING interactions reported for individual genes (e.g., MGAM–AMY2A) involve partners outside the selected gene set.
- **Regulatory interaction:** AAK1 has kinase-substrate annotations from OmniPath (source-dependent, literature-derived). MIR132 has predicted/validated mRNA targets in inflammatory pathways from literature. TGFB2-AS1 and INHBA-AS1 have putative cis-regulatory relationships to their sense partners, but these were not directly measured.
- **Co-expression:** Not computed from the uploaded data.
- **Pathway co-membership:** Multiple genes share KEGG or Reactome pathway annotations (e.g., *POMK* and *POMGNT2-AS1* in O-glycan biosynthesis; *GREM1*, *TGFB2-AS1*, *INHBA-AS1* in TGF-β signaling).
- **Indirect or putative relationship:** The connection between *FGG* and TGF-β/ECM remodeling is indirect, mediated through coagulation–inflammation crosstalk.

---

## 4. Validation Priorities

### Priority 1: Antisense lncRNA–sense partner regulatory relationships (Mechanistic hypothesis)

**Why:** The dominant signal is upregulation of dozens of antisense transcripts. Whether these regulate their sense partners (e.g., *TGFB2-AS1* → *TGFB2*, *INHBA-AS1* → *INHBA*, *SERPINB9-AS1* → *SERPINB9*) is the most mechanistically consequential question.

**Current dataset evidence:** 20+ antisense transcripts are significantly upregulated with FDR < 0.05.

**External evidence:** Literature supports lncRNA dysregulation in COPD (PMID: 34814278, 35448163), but specific functional characterization of most of these antisense transcripts is lacking.

**Next step:** Quantify sense and antisense transcript levels independently (strand-specific RT-qPCR) in COPD and control lung tissue; test whether antisense knockdown alters sense-partner expression in airway epithelial or fibroblast cell models.

**Status:** Exploratory hypothesis.

### Priority 2: GREM1 as a pro-fibrotic mediator in COPD airway remodeling (Therapeutic target)

**Why:** *GREM1* is a well-characterized BMP antagonist with established roles in pulmonary fibrosis; its upregulation in COPD lung tissue suggests it may contribute to the fibrotic component of small-airway disease.

**Current dataset evidence:** log2FC = 1.65, FDR = 0.0072.

**External evidence:** *GREM1* is implicated in IPF and chronic fibrotic lung disease in published literature; BMP antagonism is a recognized pro-fibrotic mechanism. However, direct COPD-specific evidence for *GREM1* is limited.

**Next step:** Immunohistochemistry for GREM1 in COPD versus control lung tissue; in vitro BMP reporter assays in primary human lung fibroblasts treated with COPD-relevant stimuli (cigarette smoke extract); assess whether GREM1 neutralization attenuates fibroblast activation.

**Status:** Supported hypothesis.

### Priority 3: MIR132 as an inflammatory regulatory node (Biomarker / Mechanistic hypothesis)

**Why:** miR-132 is a CREB-induced inflammatory miRNA with validated targets in TLR and cholinergic anti-inflammatory pathways; its upregulation is consistent with chronic innate immune activation in COPD.

**Current dataset evidence:** log2FC = 1.65, FDR = 0.000237.

**External evidence:** miR-132 is induced by TLR4 signaling and regulates acetylcholinesterase expression in inflammatory contexts (PMID: 34484645); miR-132 dysregulation has been reported in COPD sputum and serum studies.

**Next step:** Measure miR-132 in induced sputum or exhaled breath condensate from COPD patients versus controls; correlate with FEV1, CRP, and exacerbation frequency; test whether anti-miR-132 reduces inflammatory cytokine production in airway epithelial cells exposed to cigarette smoke extract.

**Status:** Supported hypothesis.

### Priority 4: B-cell / plasma cell infiltration as a composition confounder (Confounding or composition check)

**Why:** *IGKV1-8* (log2FC = 1.84, FDR = 0.0009) is an immunoglobulin light chain gene whose upregulation likely reflects B-cell or plasma-cell infiltration. This may confound interpretation if COPD and control groups differ in immune cell composition.

**Current dataset evidence:** *IGKV1-8* is the most strongly upregulated protein-coding gene; other immune genes (*DEFB1*, *NCR3LG1*) are also elevated.

**External evidence:** B-cell follicles and tertiary lymphoid structures are documented in COPD lung tissue, particularly in severe disease.

**Next step:** Perform cell-type deconvolution on the full transcriptomic dataset (not just the selected gene list) using CIBERSORTx or similar tools; validate B-cell/plasma-cell infiltration by CD20/CD138 immunohistochemistry in matched tissue sections; assess whether immune-cell composition correlates with disease severity.

**Status:** Supported hypothesis (for composition effect); exploratory for disease-specific B-cell biology.

### Priority 5: O-glycan biosynthesis pathway alteration (Mechanistic hypothesis)

**Why:** *POMK* and *POMGNT2-AS1* both implicate O-mannosyl glycosylation, a pathway with potential relevance to mucin biology and airway host defense.

**Current dataset evidence:** *POMK* (log2FC = 1.06, FDR = 0.0012); *POMGNT2-AS1* (log2FC = 0.95, FDR = 0.0136); KEGG mannose-type O-glycan biosynthesis retrieved.

**External evidence:** Altered mucin O-glycosylation is documented in COPD and chronic bronchitis, but *POMK*/*POMGNT2* specifically have not been studied in COPD.

**Next step:** Assess O-mannosyl glycan profiles in COPD versus control airway mucus by mass spectrometry; determine whether *POMK* expression correlates with mucin glycosylation patterns or bacterial colonization.

**Status:** Exploratory hypothesis.

---

## 5. Evidence Grounding Summary

| Conclusion | Direct Evidence (Input) | Pathway/Ontology | Protein/Regulatory Network | Disease Association | Expression/Tissue | Literature | Overall Assessment |
|---|---|---|---|---|---|---|---|
| Antisense lncRNA regulatory reprogramming | 20+ antisense transcripts, FDR < 0.05 | Reactome R-HSA-9827615 (4 genes) | TRRUST records for 2 selected genes | GWAS records for 100 genes (non-specific) | GTEx data for 43/100 genes | lncRNA in COPD/lung cancer (PMID: 34814278, 35448163) | Strong direct; weak external mechanism |
| TGF-β/BMP/ECM pro-fibrotic signaling | *GREM1*, *FGG*, *TGFB2-AS1*, *INHBA-AS1* upregulated | Hallmark TGF-β; Reactome ECM organization | No direct interactions among selected genes | *GREM1* in IPF literature | *FGG* expressed in liver/acute-phase; lung expression moderate | TGFB2-AS1 in TGF-β pathway (PMID: 33996791) | Moderate direct; moderate literature (IPF, not COPD-specific) |
| Innate/adaptive immune activation | *DEFB1*, *IGKV1-8*, *NCR3LG1* upregulated | KEGG *S. aureus* infection; GO monocyte chemotaxis regulation | No direct interactions among selected | GWAS non-specific | *DEFB1* expressed in epithelial tissues | miR-21/T-cell in MS (PMID: 34484645, contextual only) | Moderate direct; weak disease-specific external |
| O-glycan biosynthesis alteration | *POMK*, *POMGNT2-AS1* upregulated | KEGG mannose-type O-glycan biosynthesis | No direct interactions | No COPD-specific records | *POMK* low expression across GTEx tissues | Insufficient COPD literature | Weak direct; insufficient external |
| Small RNA / ribosomal biogenesis shift | *RN7SK*, *RNA18SN5*, *MIR132*, snoRNAs | No unified pathway | No regulatory network data | GWAS non-specific | snoRNA expression in lung (PMID: 34814278) | miR-132 in inflammation (PMID: 34484645) | Moderate direct; weak mechanistic external |

**Independence note:** GWAS, ClinVar, cBioPortal, and OpenTargets records were retrieved for nearly all genes but are largely non-specific (genomic variant records without COPD phenotype specificity in many cases). These sources share overlapping underlying genomic databases and should not be treated as independent evidence. Reactome and KEGG annotations derive from curated pathway databases that may share underlying literature. STRING interactions reported for individual genes involve partners outside this selected gene set and do not constitute within-cohort network evidence.

**Conflicting evidence:** No direct conflicts were identified, but a notable gap exists: the strong lncRNA/antisense signal lacks functional validation literature, while the protein-coding signals (*GREM1*, *DEFB1*, *MIR132*) have stronger external support but weaker statistical prominence in the dataset.

---

## 6. Limitations and Alternative Explanations

1. **Cell-composition confounding.** The upregulation of *IGKV1-8* strongly suggests B-cell/plasma-cell infiltration differences between COPD and control lungs. Other immune genes (*DEFB1*, *NCR3LG1*) may similarly reflect altered cell populations rather than cell-autonomous gene regulation. **Investigation:** Cell-type deconvolution on the full expression matrix; immunohistochemistry for lineage markers; single-cell RNA-seq of COPD versus control lung tissue to attribute gene expression to specific cell types.

2. **Predominance of non-coding and uncharacterized transcripts.** Over 50% of selected genes are antisense lncRNAs, LOC loci, pseudogenes, or small RNAs. These may reflect genuine regulatory changes, but may also arise from RNA quality differences, degradation patterns, or mapping artifacts in degraded lung tissue. **Investigation:** Confirm key transcripts by strand-specific RT-qPCR; assess RNA integrity number (RIN) distributions across groups; repeat analysis excluding all non-coding/LOC entries to determine whether protein-coding signals remain consistent.

3. **Disease severity and treatment exposure heterogeneity.** COPD severity (GOLD stage), smoking status, inhaled corticosteroid use, and exacerbation history were not provided. These factors profoundly influence lung transcriptomes. **Investigation:** Stratify analysis by GOLD stage, smoking pack-years, and medication use if metadata are available.

4. **Batch or platform effects.** The presence of multiple rRNA fragments (*RNA18SN5/SN1/SN3*), snoRNAs, and scaRNAs among significant features raises the possibility of platform-specific detection biases or batch effects in non-coding RNA quantification. **Investigation:** Examine principal component analysis plots for batch clustering; assess whether non-coding RNA signals persist after batch correction (e.g., ComBat).

5. **Association-versus-causation ambiguity.** All findings are observational differential expression associations. No causal inference can be drawn from this design. Upregulation of *GREM1*, *MIR132*, or antisense transcripts may be a consequence of COPD pathology rather than a driver. **Investigation:** Functional perturbation experiments (knockdown/overexpression) in relevant cell models; Mendelian randomization if GWAS instruments are available for key genes.

---

**In summary, the COPD lung tissue transcriptomic signature is dominated by a broad upregulation of antisense and non-coding RNAs, with a coherent protein-coding signal pointing toward TGF-β/BMP-mediated pro-fibrotic remodeling, innate immune activation, and possible O-glycan pathway alterations; however, the absence of independent cohort validation, the predominance of uncharacterized non-coding transcripts, and unresolved cell-composition confounding require that these conclusions be treated as supported-to-exploratory hypotheses pending functional and compositional validation.**

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=34, external claims checked=0, external mismatches=0, status=passed.

Answer model API: Zhipu AI / glm-5.2

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 67/100 selected items (records returned); cbioportal 68/100 selected items (records returned); chembl 31/100 selected items (records returned); civic 1/100 selected items (records returned); clinicaltrials 13/100 selected items (records returned); clinvar 68/100 selected items (records returned); ensembl 29/100 selected items (partially returned; some queries failed); europepmc 657 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 43/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 17/100 selected items (records returned); humanbase 89/100 selected items (partially returned; some queries failed); intact 20/100 selected items (records returned); mygene 93/100 selected items (records returned); omnipath 9/100 selected items (records returned); opentargets 65/100 selected items (records returned); pubmed 254 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 22/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 23/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 4/100 selected items (records returned); string 19/100 selected items (records returned); trrust 2/100 selected items (records returned)
